Palbo 125mg Capsule

The human body reacts differently to Palbo 125mg Capsule. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Capsule are mentioned below:

• Blurred vision
• Loss of appetite
• Sore throat
• Bleeding gums
• Difficulty in breathing
• Back pain
• Pale skin
• Unusual tiredness
• Chest pain
• Red spots on the skin
• Inflammation of the mouth
• Fever
• Rashes
• Change in taste

• Take the dose of Palbo 125mg Capsule as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you.
• This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.
• It can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.

Palbo 125mg Capsule, an anticancer medicine, work by inhibiting cyclin-dependent kinase 4 and 6; as a result, cell growth ceases or stops, arresting the cancer cell cycle. Cyclin-dependent kinase 4 and 6 (chemical messengers) play an essential role in downstream signaling pathways, which lead to the proliferation of cells. It also disrupts the cell cycle by targeting estrogen (hormone) receptor-positive breast cancer cells.

Palbo 125mg Capsule, an anticancer medicine, work by inhibiting cyclin-dependent kinase 4 and 6; as a result, cell growth ceases or stops, arresting the cancer cell cycle. Cyclin-dependent kinase 4 and 6 (chemical messengers) play an essential role in downstream signaling pathways, which lead to the proliferation of cells. It also disrupts the cell cycle by targeting estrogen (hormone) receptor-positive breast cancer cells.

• Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., ... & Cristofanilli, M. (2018). Overall survival with palbociclib and fulvestrant in advanced breast cancer. New England journal of medicine, 379(20), 1926-1936.
• Wedam, S., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., ... & Beaver, J. A. (2020). FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clinical Cancer Research, 26(6), 1208-1212.
• Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., ... & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England journal of medicine, 375(20), 1925-1936.
• Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F., & Palumbo, R. (2019). Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs in context, 8, 212579.
• Cadoo, K. A., Gucalp, A., & Traina, T. A. (2014). Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy, 123-133.
• Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., ... & Cristofanilli, M. (2015). Palbociclib in hormone-receptor–positive advanced breast cancer. New England Journal of Medicine, 373(3), 209-219.